Trajan Scientific and Medical (Trajan) is now a member of BioMelbourne Network. As a group of companies with headquarters in Melbourne, Trajan is looking forward to strengthening connections with local scientific organisations, business leaders and government.
Stephen Tomisich, Trajan’s Chief Executive Officer said, “We hope our membership helps us to engage with other members to support and contribute to the success of the Australian scientific industry, in particular biotechnology in Victoria.
“We are proud to be an Australian owned and operated global company, building on humble beginnings in Ringwood with SGE Analytical Science over 50 years ago, growing to develop new analytical technologies for the scientific community and society.”
Trajan’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, especially those that can lead to portability, miniaturization and affordability.
“We seek opportunities for each of our companies with their unique capabilities. Trajan is able to facilitate collaboration with one or more of our companies in Australia and around the world.” said Robert Lyon, Head of Corporate Development at Trajan.
Trajan encompasses a group of companies including SGE Analytical Science, Grale HDS and SciMed Precision with over 300 staff worldwide, and customers in over 100 countries.
SGE Analytical Science is a world leader in creating components and consumables used in scientific analysis. SGE has substantial capability in materials science, chemistry, fabrication and distribution.
SciMed Precision offers complete solutions in design and production engineering of high precision complex components for analytical and life science applications.
Grale HDS is a pathology supply partner like no other. Supplying quality products for more than 30 years, they assist laboratory managers tackle operational challenges.
“Through true customer focus and partnerships, we aim to make a positive impact on the world of analytical and medical science.” said Mr Tomisich.
BioMelbourne Network www.biomelbourne.org
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.